ARTICLE | Company News
BTG, Senexis deal
February 6, 2006 8:00 AM UTC
BGC granted Senexis an exclusive license to preclinical compounds that inhibit amyloid-induced toxicity and neuroinflammation to treat Alzheimer's disease (AD) and other amyloid-based diseases. BGC is...